Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim

Published: Tuesday, December 10, 2013
Last Updated: Tuesday, December 10, 2013
Bookmark and Share
The milestone relates to the transition of an oncology molecule into pre-clinical development.

Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec. 

Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This is the twenty-first milestone achieved as part of our alliance with Boehringer Ingelheim and represents a third oncology compound transitioning into pre-clinical development of which one is already in Phase I clinical trials. Our collaboration with Boehringer Ingelheim continues to support Evotec’s overall strategy of building up a pipeline of assets of which we have interest in future upside.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Awarded Contract to Manage NCI CBC Screening Libraries Center
Company will provide compound management services for a period of five years.
Friday, October 09, 2015
Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec, Fraunhofer in Drug Discovery Collaboration
The exclusive, strategic collaboration will combine the relevant platforms of both organisations, focusing on several disease areas.
Tuesday, July 08, 2014
Evotec Enters Biology Collaboration with Probiodrug
Evotec will setup and validate assays to support the pre-clinical and clinical development of QC inhibitors in Alzheimer’s disease.
Thursday, November 29, 2012
Evotec Receives Pre-clinical Milestone Payment
Evotec AG announces that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec.
Friday, August 19, 2011
Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression
The proof-of-concept Phase II trial will study the safety and tolerability of EVT 101 while also exploring the efficacy of this intervention.
Thursday, July 01, 2010
Evotec Reports Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche
Company completion its first-in-man study with EVT 103 and receives a positive feedback from the FDA to initiate Phase II with EVT 101.
Thursday, March 11, 2010
Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical
Ono to access Evotec’s ion channel drug discovery platform and expertise and Evotec to receive research funding and milestone payments.
Monday, October 19, 2009
Evotec Starts Phase I with EVT 103, an NR2B-selective NMDA Receptor Antagonist
EVT 103 is currently planned to enter clinical development for treatment-resistant depression in collaboration with Roche.
Wednesday, September 09, 2009
Evotec Announces the Successful Completion of the First Phase I Study with EVT 401
The double-blind, placebo controlled study showed that the compound was safe and well tolerated without any serious adverse events.
Friday, July 10, 2009
Evotec Acquires Zebrafish Screening Operations of Summit Corporation
The acquisition against £ 0.5 million cash in 2009 expected to add approximately £ 1.5 million revenues in 2010.
Friday, May 08, 2009
Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302
Study fails to demonstrate any significant improvement in the quit rate compared with placebo.
Monday, April 20, 2009
Evotec Presents its Fragment Screening Technology at Two Key Conferences
Presentations will be given at Screening, MedChem and ADMET Europe and at the Molecular Medicine Tri-Conference.
Thursday, February 19, 2009
Evotec Reports Phase I Safety Data from Tyramine Interaction Study with EVT 302
The study was undertaken to determine potential safety advantages of EVT 302 versus non-selective MAO inhibitors and less selective MAO-B inhibitors.
Monday, November 03, 2008
Evotec Announces Phase I Initiation with P2X7 Antagonist
P2X7 receptor antagonism may provide a novel approach to the treatment of rheumatoid arthritis and other inflammatory conditions.
Friday, October 10, 2008
Scientific News
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!